Volume 6, Issue 12

Barriers To Minority Participation in MS Clinical Trials

In this issue:

In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?

Join guest author Dr. Mima Akinsanya, from the Department of Neurology at the Georgetown University Medical Center, as we discuss the answers to these questions in this issue of eMultipleSclerosis Review.

Learning objective:

Explain the limitations of clinical trials that lack inclusive representation of people from racial and ethnic minority groups. 

Author:

Mima (Jemima) Akinsanya, DO
Mima (Jemima) Akinsanya, DO

Assistant Professor, Department of Neurology
Georgetown University Medical Center
Director, Multiple Sclerosis Clinic - Georgetown Neurology at Clinton
Washington, DC

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 25, 2025
Expiration date: March 24, 2027